Cadence Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Cadence Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-30,556	Closed	-$102K	–	469
2019 Q3	$102K	Buy	+30,556	New	+$101K	0.01%	405
2014 Q3	–	Sell	-304,145	Closed	-$812K	–	602
2014 Q2	$812K	Sell	304,145 -33,447	-10%	-$101K	0.04%	437
2014 Q1	$1.18M	Buy	337,592 +58,082	+21%	+$258K	0.05%	416
2013 Q4	$1.25M	Buy	+279,510	New	+$1.14M	0.05%	387

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Cadence Capital Management's ATRS Position: Q4 2019 in Review

Cadence Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q4 2019, closing a stake of 30,556 shares — an estimated $102K sold.

Cadence Capital Management first reported a position in ATRS in Q4 2013 and held it in 4 quarters. The position peaked at $1.25M in Q4 2013. 160 funds tracked by Wall St. Rank hold ATRS as of Q4 2019.

Cadence Capital Management reported no remaining Antares Pharma, Inc. position as of Q4 2019 after selling out during the quarter.
Cadence Capital Management sold 30,556 Antares Pharma, Inc. shares in Q4 2019, an estimated $102K.
Cadence Capital Management first reported a position in Antares Pharma, Inc. in Q4 2013 and held it in 4 quarters.
Cadence Capital Management's Antares Pharma, Inc. position peaked at $1.25M in Q4 2013.
160 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2019.

Based on Cadence Capital Management's 13F filing for Q4 2019, filed 3 Feb 2020.